COVID-19 Clinical Trials and Expanded Access

To respond to the COVID-19 pandemic, investigators will be deploying community healthworkers, equipped with mobile technology, and accompanied by youth to visit householdsdoor to door to screen for symptoms of COVID-19, isolate, test, and manage suspectedcases of COVID-19. The community health workers and youth will educate households aboutpreventive measures including frequent handwashing and home management of mild cases.Simultaneously, investigators will work with nurses, doctors, and clinical officers, totest and treat more severe cases of COVID-19 in health facilities. Our goals are: tovisit every household in Siaya county covering a population of close to 1 million, and totrain and support health workers working in 32 health facilities with oxygen capacity inSiaya to reduce the morbidity and mortality related to COVID19 and other conditions.

The CVP-COVID19 registry is both a retrospective and prospective study design in order toidentify predictors of cardiovascular disease progression and mortality for COVID-19. Theregistry enrolls consecutive patients with positive microbiological tests for SARS-CoV-2admitted to an academic hospital in northern Italy for worsening of COVID-19 symptoms.The study does not test any new diagnostic or therapeutic approach. Patients are treatedaccording to good clinical practice. Patients characteristics, including medical history(with particular attention to cardiovascular and pneumological risk factors), features ofphysical examination, results laboratory and radiological tests and treatments (pre- andin-hospital) are related with patient outcome. Logistic analysis (univariate,multivariate and propensity) are performed in order to identify factors associated withdisease progression. Primary endpoint: mortality.

This is a multi-center, observational study that will enroll 1) patients with severeCOVID-19 who have agreed to undergo therapy with Seraph® 100 under the existing EUA; 2)patients (medical record data) that have been previously treated with the Seraph® 100after the date of the EUA approval (17 April 2020), but before the date that the study isapproved at the study site, and 3) a convenience sample of patients (medical record data)in a historical control group who were admitted to the ICU at participating sites withsevere COVID-19 infection, meeting the EUA treatment criteria, but not treated withSeraph® 100 up to the time the PURIFY-OBS protocol is approved at the site

COVID19 patients survivors, after discharge from hospital show reduced lung function andreduced ability to exercise. Furthermore, mental health problems including stress,anxiety and depression and a low quality of life were observed. The prospectiveobservational study involves COVID19 patients who have needed rehabilitation at theUniversity Hospital of Ferrara. Patients receive comprehensive rehabilitation based ontheir specific needs in both acute and subacute rehabilitation. At the end of hospitalrehabilitation, patients are offered a program to be carried out at home for bothphysical and psychological problems. A range of demographic and clinical data will becollected. Patients will also undergo a battery of functional, cognitive andpsychological tests at 12, 26 and 52 weeks from the infection onset. Moreover, a specificassessement (both clinical and instrumental) on the pain symptom experienced, wherepresent, will be done.

Study objective is to evaluate the efficacy of the combination of masitinib andisoquercetin in adult hospitalized patients with moderate and severe COVID-19.

This study is to establish an accurate, robust and easily scalable COVID-19 viral nucleicacid analysis platform from, but not limited to, saliva to help enable and supportcontact tracing in the canton of Baselland/ Switzerland. To achieve this, cruderibonucleotide acid (RNA) extraction from saliva is validated in combination withnext-generation sequencing (NGS) diagnostics and loop mediated amplification (LAMP)assays as well as point of care test (POCT) for rapid detection of viral antigens onpatients' samples.

The purpose of the study is to Assess of Long-term impact post COVID for patients andhealth care professionals.The patients and medical staff will be followed for 2 years inorder to provide clinical and paraclinical data not yet published in the literature.

COVID-19 is associated with acute pulmonary and cardiac injury. To better understand thedegree and severity of cardiopulmonary injury as well as short and long-term sequelae ofCOVID-19 infection, this study will perform longitudinal study in patients who had recentknown diagnosis of COVID-19.

Coronavirus has caused containment of more than a third of the world's population. Somecountries have used a major screening strategy. Screening procedures, such as waiting (orresulting) for the test, can be stressful and can attract the most stressed people.However, there is currently no data on the relationship between stress and screening forSARS-CoV2

Currently, there is no approved treatment for COVID-19 in France, either for the acutephase, nor for the late chronic phase. the investigator suggest that nintedanib has thepotential to block the development of lung fibrosis when initiated early enough toinhibit the activation of mesenchymal cells and the progression of virus-inducedpulmonary fibrosis. Computerized Tomography (CT) manifestations of fibrosis or fibrousstripes are described in COVID-19 (Ye, Eur Radiol 2020). Pan et al observed fibrousstripes in 17% patients in the early phase of the disease (Pan, Eur Radiol 2020). Ye etal observed bronchiectasis in 2 patients (15.4%) and evidence of pulmonary fibrosis in 3patients (23.7%) at HRCT performed at 4 weeks (Ye, Eur Radiol 2020). Long term data arestill lacking in patients with COVID-19 and the investigators do not know how manypatients will have fibrotic sequelae from the acute illness.